Home / Companies / Recibiopharm / Trends
Recibiopharm H-1B trends
Quarterly LCA aggregate trend points for Recibiopharm. Each point carries filing counts, distinct employers, distinct role titles, SOC coverage, wage metrics, certification counts, and source IDs when returned.
| Period | LCA count | Role titles | SOC codes | Avg wage low | Avg prevailing | Certified | Certification rate |
|---|---|---|---|---|---|---|---|
| 2021 Q1 | 1 | 1 | 1 | $154,000 | $153,837 | 1 | 100.0% |
| 2021 Q2 | 1 | 1 | 1 | $154,000 | $153,837 | 1 | 100.0% |
| 2021 Q3 | 2 | 2 | 1 | $142,000 | $124,956 | 2 | 100.0% |
| 2021 Q4 | 2 | 1 | 2 | $130,000 | $104,073 | 2 | 100.0% |
| 2022 Q4 | 1 | 1 | 1 | $125,000 | $108,410 | 1 | 100.0% |
| 2023 Q2 | 2 | 2 | 1 | $130,000 | $110,687 | 2 | 100.0% |
| 2023 Q3 | 1 | 1 | 1 | $100,000 | $96,616 | 1 | 100.0% |
| 2023 Q4 | 3 | 3 | 3 | $145,000 | $118,394 | 3 | 100.0% |
| 2024 Q2 | 1 | 1 | 1 | $95,000 | $94,141 | 1 | 100.0% |
| 2024 Q3 | 2 | 2 | 2 | $107,995 | $103,616 | 2 | 100.0% |
| 2024 Q4 | 2 | 2 | 2 | $97,500 | $92,009 | 2 | 100.0% |
| 2025 Q1 | 1 | 1 | 1 | $85,000 | $68,744 | 1 | 100.0% |
| 2025 Q3 | 1 | 1 | 1 | $125,000 | $107,099 | 1 | 100.0% |
| 2026 Q2 | 2 | 2 | 2 | $164,665 | $128,326 | 2 | 100.0% |
Get this page with API
Rendered from the bluedoor H-1B Jobs API. Reproduce it:
GET https://api.bluedoor.sh/h1b-jobs/v1/trends?company=recibiopharm&metric=lca_countJSON